Jak2 V617f Mutation - Histology

Relevant Publications

ADAMTS13, von Willebrand Factor, Platelet Microparticles, Factor VIII, and Impact of Somatic Mutations in the Pathogenesis of Splanchnic Vein Thrombosis Associated with BCR-ABL-Negative Myeloproliferative Neoplasms.

Issue Release: 2024

Determinants of mosaic chromosomal alteration fitness.

Issue Release: 2024

IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.

Issue Release: 2024

The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.

Issue Release: 2024

Ischemic stroke as an initial performance of polycythemia vera in young adults: A case report and literature review.

Issue Release: 2024

Loss of Dnmt3a increased self-renewal and resistance to pegIFNα in JAK2-V617F-positive myeloproliferative neoplasms.

Issue Release: 2024

[leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) inhibits proliferation and promotes apoptosis of human HEL cells with JAK2 V617F mutation by blocking the JAK/STAT and PI3K/AKT signaling pathways].

Issue Release: 2024

Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR.

Issue Release: 2024

A 27-Year-Old Female With JAK2 Mutation: A Case of Budd-Chiari Syndrome Secondary to Prolonged Oral Contraceptive Pill Use.

Issue Release: 2024

Programmed death-ligand 1 expression in patients with primary or secondary myelofibrosis.

Issue Release: 2024

Combination of ligand‑based and structure‑based virtual screening for the discovery of novel Janus kinase 2 inhibitors against philadelphia-negative myeloproliferative neoplasms.

Issue Release: 2024

Challenges in Diagnosing Polycythemia Vera in Primary Care: A 55-Year-Old Malaysian Woman with Atypical Presentation.

Issue Release: 2024

Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry.

Issue Release: 2024

Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative Review.

Issue Release: 2024

Repeated Ischemic Stroke due to in situ Thrombus at the Middle Cerebral Artery in a Patient with Essential Thrombocythemia.

Issue Release: 2024

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms.

Issue Release: 2024

Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study.

Issue Release: 2024

Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia.

Issue Release: 2024

Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.

Issue Release: 2024

Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk.

Issue Release: 2024

What are the Side Effects of Radiation Therapy?

What Types of Tissue Cultures Exist?

How Does Open Science Improve Collaboration?

What is the Role of GLUT2 in Glucose Homeostasis?

What are the Types of Safety Engineered Sharps Used in Histology?

How Do Facility Costs Affect the Budget?

What Comprises the OBRB?

What are some notable achievements of IFSHC?

Why is De-identification Important?

When are Emergency Biopsies Needed?

Partnered Content Networks

Relevant Topics